Last reviewed · How we verify
CT7001
At a glance
| Generic name | CT7001 |
|---|---|
| Also known as | Samuraciclib |
| Sponsor | Carrick Therapeutics Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (PHASE1, PHASE2)
- Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT7001 CI brief — competitive landscape report
- CT7001 updates RSS · CI watch RSS
- Carrick Therapeutics Limited portfolio CI